Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis
Ikki Sakuma(Chiba University), Gerald I. Shulman(Howard Hughes Medical Institute), Traci E. LaMoia(Yale University), Mario Kahn(Yale University), Mateus T. Guerra(Yale University), Daniel F. Vatner(Veterans Health Administration), Mark Perelis(Northwestern University), Michael Roden(Düsseldorf University Hospital), S. Kahl(Düsseldorf University Hospital), Maximilian Huttasch(Deutsches Diabetes-Zentrum e.V.), Tomoaki Tanaka(Chiba University), Yusuke Kawashima, Varman T. Samuel(VA Connecticut Research and Education Foundation), Sylvie Dufour(Yale University), Dean Yimlamai(Yale University), Jie Zheng(City University of Hong Kong), Yuki Taki(Chiba University), Ali Nasiri(Yale University), Kitt Falk Petersen(Yale University), Birgit Knebel(Deutsches Diabetes-Zentrum e.V.), Rafael Calais Gaspar(Universidade Estadual de Campinas (UNICAMP))
Cited by 33
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Effects of free fatty acids on glucose transport and IRS-1–associated phosphatidylinositol 3-kinase activity
|Journal of Clinical Investigation|1999|1.3k